Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-part Study to Assess the Safety, Antiviral Biomarker Responses, and Efficacy of Inhaled SNG001 for the Treatment of Patients With a Confirmed Respiratory Virus Infection Undergoing Invasive Mechanical Ventilation

NCT06999603 is registered in ClinicalTrials.gov with Synairgen Research Ltd. as lead sponsor.

NCT NCT06999603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06999603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-part Study to Assess the Safety, Antiviral Biomarker Responses, and Efficacy of Inhaled SNG001 for the Treatment of Patients With a Confirmed Respiratory Virus Infection Undergoing Invasive Mechanical Ventilation
Lead sponsor
Synairgen Research Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2025
Completion date
March 13, 2026
Enrollment
11 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

viral pneumonia